BioCentury | Oct 27, 2020
Product Development

Oct. 26 Quick Takes: COVID trips up Spectrum’s Rolontis at FDA; plus Jazz-SpringWorks, Novartis’ iptacopan, Kantaro, Eternygen

...offices. The round will remain open to raise additional funds to bring the company’s preclinical SLC13A5...
BioCentury | May 12, 2014
Company News

Eternygen, Evotec deal

...Evotec will discover small molecule inhibitors against solute carrier family 13 sodium-dependent citrate transporter member 5 (SLC13A5) to treat metabolic diseases. Eternygen, which operates as...
BioCentury | Aug 18, 2011
Distillery Therapeutics

Indication: Endocrine disease

...SLC13A5 could help treat obesity and type 2 diabetes. In mice fed a high-fat diet, Slc13a5...
...body mass and better hepatic insulin responsiveness than Slc13a5 expression. Next steps could include studying SLC13A5...
Items per page:
1 - 3 of 3